Alto Neuroscience (ANRO) Total Non-Current Liabilities (2023 - 2024)
Alto Neuroscience (ANRO) posted Total Non-Current Liabilities of $26.1 million for Q4 2024, down 1.78% sequentially from $26.6 million in Q3 2024, and up 68.59% YoY from $15.5 million in Q1 2024.
Powered by 
Analysis
Alto Neuroscience (ANRO) Total Non-Current Liabilities (2023 - 2024) Analysis & Trends
Alto Neuroscience has reported Total Non-Current Liabilities for 2 years, with the latest figure at $26.1 million in Q4 2024.
- Quarterly Total Non-Current Liabilities rose 68.59% year-over-year to $26.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $26.1 million (up 68.59% YoY) and the FY2024 annual result came in at $26.1 million, up 68.59% from the prior year.
- Total Non-Current Liabilities declined to $26.1 million in Q4 2024 per ANRO's latest filing, from $26.6 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $26.6 million in Q3 2024 and troughed at -$1.7 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Alto Neuroscience | 1.52 Bn | 1.52 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 26.08 Mn |
| Sep 30, 2024 | 26.56 Mn |
| Jun 30, 2024 | 17.58 Mn |
| Mar 31, 2024 | 16.82 Mn |
| Dec 31, 2023 | 15.47 Mn |
| Sep 30, 2023 | 59.70 Mn |
| Jun 30, 2023 | 51.00 Mn |
| Mar 31, 2023 | 43.53 Mn |